文献速递白血病淋巴瘤

创建新型翻译抑制剂靶向慢性淋巴细胞白血病中的促生存蛋白

Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2019-01-30

慢性淋巴细胞白血病(CLL)细胞存活依赖抗凋亡蛋白Mcl-1的持续再合成。本研究基于海洋天然产物Pateamine A(PatA)合成衍生物,发现DMDAPatA可阻断mRNA翻译、降低Mcl-1蛋白并诱导CLL细胞凋亡,与Bcl-2拮抗剂ABT-199协同;但DMDAPatA与人血浆蛋白结合强限制了效力。据此合成新系列PatA类似物,获得三个翻译抑制活性强、血浆蛋白结合少、对CLL细胞细胞毒活性更高且对正常淋巴细胞选择性更好的先导化合物,计算机模拟提示其可能通过稳定eIF4A闭合构象发挥作用。

要点

  • DMDAPatA阻断mRNA翻译、降低Mcl-1蛋白并诱导CLL细胞凋亡,与ABT-199协同。
  • DMDAPatA与人血浆蛋白结合强限制其效力,妨碍进一步开发。
  • 新PatA类似物血浆蛋白结合更少、对CLL细胞细胞毒活性更高、对正常淋巴细胞选择性更好。

核心结论

  • 新型PatA类似物在适当生物学背景(如CLL)的癌症中具有应用前景。

研究设计与样本

  • 本研究为体外研究,评估PatA合成衍生物DMDAPatA及新合成PatA类似物对CLL细胞的作用。

主要发现

  • DMDAPatA阻断mRNA翻译、降低Mcl-1蛋白并诱导CLL细胞凋亡,与Bcl-2拮抗剂ABT-199协同。
  • DMDAPatA与人血浆蛋白结合强,限制其效力,妨碍进一步开发。
  • 新合成PatA类似物中鉴定出三个先导化合物,翻译抑制活性强,血浆蛋白结合少于DMDAPatA,对CLL细胞细胞毒活性高于DMDAPatA,对CLL细胞选择性优于正常淋巴细胞。
  • 计算机模拟分析关联了构效关系,并提示这些化合物可能通过稳定eIF4A闭合构象发挥作用。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure-activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Chen R, Zhu M, Chaudhari RR, et al. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia. 2019. PMID: 30700841. doi:10.1038/s41375-018-0364-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。